A C-Met Inhibitor Increases the Chemosensitivity of Cancer Stem Cells to the Irinotecan in Gastric Carcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 Oct 17

PMID 24129235

Citations 31

Authors

M Yashiro

T Nishii

T Hasegawa

T Matsuzaki

T Morisaki

T Fukuoka

K Hirakawa

Affiliations

Soon will be listed here.

Abstract

Background: Cancer stem cells (CSCs) may be postulated mediators of the chemoresistance. This study aimed to determine an effective signal inhibitor with effects on the proliferation of CSCs in combination with anticancer drugs.

Methods: We used three gastric cancer cell lines and three side population (SP)-enriched CSC cell lines. We examined the combined effects of inhibitors against stemness signals, including c-Met inhibitor SU11274, and five anticancer drugs on the CSC proliferation and mRNA expression of chemoresistance-associated genes.

Results: The IC50 of irinotecan in SP-enriched CSC was 10.5 times higher than parent OCUM-2M cells, whereas that of oxaliplatin, taxol, gemcitabine, and 5-fluorouracil was 2.0, 2.8, 2.0, and 1.2, respectively. The SP cell lines had higher expression levels of UGT1A1, ABCG2, and ABCB1 than their parent cell lines. There was a synergistic antiproliferative effect with a combination of SU11274 and SN38 in SP cells, but not other inhibitors. The SU11274 significantly decreased the expression of UGT1A1, but not ABCG2 and ABCB1. The SN38 plus SU11274 group more effectively suppressed in vivo tumour growth by OCUM-2M/SP cells than either group alone.

Conclusion: Cancer stem cells have chemoresistance to irinotecan. The c-Met inhibitor may be a promising target molecule for irinotecan-based chemotherapy of gastric cancer.

Citing Articles

Cancer molecular subtyping using limited multi-omics data with missingness.

Bu Y, Liang J, Li Z, Wang J, Wang J, Yu G PLoS Comput Biol. 2024; 20(12):e1012710.

PMID: 39724112 PMC: 11709273. DOI: 10.1371/journal.pcbi.1012710.

Research progress on the development of hepatocyte growth factor/c-Met signaling pathway in gastric cancer: A review.

Wei W, Hong Y, Deng Y, Wang G, Qiu J, Pan F World J Gastrointest Oncol. 2024; 16(8):3397-3409.

PMID: 39171189 PMC: 11334049. DOI: 10.4251/wjgo.v16.i8.3397.

Ferroptosis regulating lipid peroxidation metabolism in the occurrence and development of gastric cancer.

Wang L, Zhang W, Qiu Y, Wang F World J Gastrointest Oncol. 2024; 16(6):2781-2792.

PMID: 38994139 PMC: 11236228. DOI: 10.4251/wjgo.v16.i6.2781.

Decoding gene regulatory circuitry underlying TNBC chemoresistance reveals biomarkers for therapy response and therapeutic targets.

Lusby R, Zhang Z, Mahesh A, Tiwari V NPJ Precis Oncol. 2024; 8(1):64.

PMID: 38472332 PMC: 10933292. DOI: 10.1038/s41698-024-00529-6.

Macrophage-derived exosomes regulate gastric cancer cell oxaliplatin resistance by wrapping circ 0008253.

Yu D, Chang Z, Liu X, Chen P, Zhang H, Qin Y Cell Cycle. 2022; 22(6):705-717.

PMID: 36416404 PMC: 9980452. DOI: 10.1080/15384101.2022.2146839.

References

Wang J, Hsieh J, Chen C, Tzou W, Cheng T, Chen F . Alterations of APC, c-met, and p53 genes in tumor tissue and serum of patients with gastric cancers. J Surg Res. 2004; 120(2):242-8. DOI: 10.1016/j.jss.2003.12.018. View

Yashiro M, Chung Y, Nishimura S, Inoue T, Sowa M . Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Clin Exp Metastasis. 1996; 14(1):43-54. DOI: 10.1007/BF00157685. View

Farhat F . A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med Oncol. 2007; 24(2):137-46. DOI: 10.1007/BF02698032. View

Yashiro M, Chung Y, Inoue T, Nishimura S, Matsuoka T, Fujihara T . Hepatocyte growth factor (HGF) produced by peritoneal fibroblasts may affect mesothelial cell morphology and promote peritoneal dissemination. Int J Cancer. 1996; 67(2):289-93. DOI: 10.1002/(SICI)1097-0215(19960717)67:2<289::AID-IJC22>3.0.CO;2-5. View

Sattler M, Pride Y, Ma P, Gramlich J, Chu S, Quinnan L . A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003; 63(17):5462-9. View

Yashiro M, Chung Y, Nishimura S, Inoue T, Sowa M . Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis. Br J Cancer. 1995; 72(5):1200-10. PMC: 2033934. DOI: 10.1038/bjc.1995.486. View

Kohne C, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N . Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer. 2003; 89(6):997-1001. PMC: 2376958. DOI: 10.1038/sj.bjc.6601226. View

Yashiro M, Chung Y, Sowa M . Role of orthotopic fibroblasts in the development of scirrhous gastric carcinoma. Jpn J Cancer Res. 1994; 85(9):883-6. PMC: 5919589. DOI: 10.1111/j.1349-7006.1994.tb02963.x. View

Kondo T, Setoguchi T, Taga T . Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A. 2004; 101(3):781-6. PMC: 321758. DOI: 10.1073/pnas.0307618100. View

10.

Li Y, Li A, Glas M, Lal B, Ying M, Sang Y . c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A. 2011; 108(24):9951-6. PMC: 3116406. DOI: 10.1073/pnas.1016912108. View

11.

Fillmore C, Kuperwasser C . Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man?. Breast Cancer Res. 2007; 9(3):303. PMC: 1929090. DOI: 10.1186/bcr1673. View

12.

Innocenti F, Liu W, Chen P, Desai A, Das S, Ratain M . Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes. Pharmacogenet Genomics. 2005; 15(5):295-301. DOI: 10.1097/01213011-200505000-00004. View

13.

Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Tanaka K . Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer. 2011; 130(12):2912-21. DOI: 10.1002/ijc.26330. View

14.

Reddiconto G, Toto C, Palama I, De Leo S, de Luca E, De Matteis S . Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells. Blood. 2012; 119(10):2335-45. DOI: 10.1182/blood-2011-06-361261. View

15.

Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E . Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun. 1992; 189(1):227-32. DOI: 10.1016/0006-291x(92)91548-5. View

16.

Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, DEmidio S . Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol. 2011; 29(36):4789-95. DOI: 10.1200/JCO.2011.36.7706. View

17.

Tahara E . Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004; (157):327-49. View

18.

Inoue T, Chung Y, Yashiro M, Nishimura S, Hasuma T, Otani S . Transforming growth factor-beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Jpn J Cancer Res. 1997; 88(2):152-9. PMC: 5921364. DOI: 10.1111/j.1349-7006.1997.tb00360.x. View

19.

Jedema I, Barge R, Frankel A, Willemze R, Falkenburg J . Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins. Exp Hematol. 2004; 32(2):188-94. DOI: 10.1016/j.exphem.2003.11.005. View

20.

Dean M, Fojo T, Bates S . Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-84. DOI: 10.1038/nrc1590. View